Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

Breast Cancer Research and Treatment

Volumn 47, Issue 1, 1998, Pages 47-55

  Degeorges, Armelle ^a   De Roquancourt, Anne ^a   Extra, Jean Marc ^a   Espie, Marc ^a   Bourstyn, Edwige ^b   De Cremoux, Patricia ^b   Soussi, Thierry ^b   Marty, Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Adjuvant chemotherapy; Breast carcinoma; Immunohistochemistry; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; PEROXIDASE; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER INFILTRATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG PROTEIN BINDING; EMBOLISM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031964170     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005824216444     Document Type: Article

References (38)

1. Mansour G, Gray R, Shatila A, Osborne C, Tormey D, Gilchrist K, Cooper M, Falkson G: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an inter group study. N Engl J Med 320: 485-478, 1989
2. Fisher B, Redmond C, Dimitrov N, Bowman D, Legaut-Poisson S, Wickerham L, Wolmark N, Fisher E, Margolese R, Sutherland C, Glass A, Foster R, Caplan R et al.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320: 473-478, 1989
3. McGuire W, Clark G: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
4. Chang J, Kim DH, Lee SW, Choi KY, Sung YC: Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. J Biol Chem 270: 25014-25019, 1995
5. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer - a review. Int J Cancer 57: 1-9, 1994
6. Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Gen Devel 4: 1-8, 1990
7. Lane DP: On the expression of the p53 protein in human cancer. Mol Biol Rep 19: 23-29, 1994
8. Frebourg T, Friend SH: The importance of p53 gene alterations in human cancer - is there more than circumstantial evidence? J Natl Cancer Inst 85: 1554-1557, 1993
9. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
10. Bloom H, Richardson W: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
11. Jacobs T, Priolleau J, Stillman I, Schnitt S: Loss of tumor marker immunostaining intensity on stored paraffin slides of breast cancer. 88: 1054-1059, 1996
12. Martinazzi M: Expression of p53 oncoprotein in different histological types of breast carcinoma. Am J Pathol 144: 205, 1994
13. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: p53 and c-erbB-2 protein expression in breast carcinomas - an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408-418, 1992
14. Visscher DW, Sarkar FH, Wykes S, Kothari K, Macoska J, Crissman J: Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 117: 973-976, 1993
15. Cattoretti G, Rilke F, Anderola S, Damato L, Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988
16. Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TWJ, Horne CHW: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-35, 1996
17. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114, 1992
18. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, DiFronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993
19. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-476, 1993
20. MacGrogan G, Bonichon F, Demascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36: 71-81, 1995
21. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJW, Angus B, Horne CHW: p53 expression in human breast cancer related to survival and prognostic factors - an immunohistochemical study. J Pathol 164: 75-81, 1991
22. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51-56, 1993
23. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177: 225-232, 1995
24. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13: 821-830, 1995
25. Thor AD, Yandell DW: Prognostic significance of p53 over-expression in node-negative breast carcinoma - preliminary studies support cautious optimism. J Natl Cancer Inst 85: 176-177, 1993
26. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinoma - a review of the literature involving over 9,000 patients. 4: 106-116, 1996
27. Fan SJ, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994
28. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
29. Tsang NM, Nagasawa H, Li CY, Little JB: Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10: 2403-2408, 1995
30. Delia D, Mitzutani S, Lamorte G, Goi K, Iwata S, Pierotti M: p53 activity and chemotherapy. Nat Med 2: 724-725, 1996
31. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Deniers GW, Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996
32. Hawkins D, Deniers G, Galloway D: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996
33. Wu GS, El-Deiry WS: P53 and chemosensitivity. Nat Med 2: 255-256, 1996
34. Aas T, Borensen A, Geisler S, Varhaug J, Akslen L, Lonning P: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996
35. Stal O, Askmalm MS, Wingren S, Rutqvist LE, Skoog L, Ferraud L, Sullivan S, Carstensen J, Nordenskjold B: p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 34: 767-770, 1995
36. Jansson T, Inganas M, Sjogren S, Norherg T, Lindgren A, Holmberg L, Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13: 2745-2751, 1995
37. O'Connor DJ, Lam EWF, Griffin S, Zhong S, Leighton LC, Burbidge SA, Lu X: Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 14: 6184-6192, 1995
38. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995